These alternate strategies include using small - molecule drugs that affect RNA metabolism or protein stability, as well as administering modified viruses
for therapeutic gene delivery (see «Getting a fix on SMA»).
Not exact matches
The OAR proposal uses a variation of
therapeutic cloning called altered nuclear transfer (ANT) in which the nucleus of a donor cell (a skin cell,
for example), containing the 30,000
genes of the genetic code, is altered in such a way that it produces an epigenetic factor, a protein called nanog.
«The advantage of being able to adjust a set of
genes identified as key autism risk factors may explain the strong and long - lasting efficacy of this
therapeutic agent
for autism.»
«My team at Nationwide Children's has worked with commitment and dedication to develop a therapy that may subsequently be shown through future clinical trials to potentially alter the course of this unforgiving condition and provide a
therapeutic option
for the families and infants with SMA1,» says Jerry Mendell, MD, principal investigator in the Center
for Gene Therapy at Nationwide Children's.
The problem, Sweeney says, is that the viruses researchers use
for delivering
therapeutic genes infect primates but not other mammals.
This fact is rooted in a packaging problem: the
gene encoding FIX is much smaller than the
gene for FVIII, and better fits into a vector, usually a harmless virus, designed to deliver
therapeutic genes to a patient.
For gene therapies, scientists remove most of the AAV genome, replace it with
therapeutic genetic cargo, and inject trillions of copies into the patient.
To use viruses as delivery vehicles
for gene therapy, researchers take all the harmful and replicative
genes out of the virus and put in the
therapeutic genes they want to deliver.
«We showed that the deletion of the
gene responsible
for this pathway can restore the original
therapeutic function of the cells,» said Prof. Leor.
«The number of protein functions that are currently targeted by drugs is incredibly small compared to the total number of protein interactions that could be targeted
for therapeutic benefit,» says Geoffrey Wahl, a professor in Salk's
Gene Expression Laboratory.
This work provides a proof of principle
for a new approach in the study and treatment of cancer: the aberrant expression in a tissue or organ of
genes specific to other tissues could become a new tool
for establishing a prognosis and personalizing
therapeutic care.
The researchers are now investigating the effects of these
genes» mutations as possible targets
for new
therapeutic treatments.
In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential
therapeutic strategy
for the treatment of cancers with the BRAF mutated
gene.
«Our
gene therapy protocol is not yet ready
for clinical trials — we need to tweak it a bit more — but in the not - too - distant future we think it could be developed
for therapeutic use in humans,» says Jeffrey Holt, PhD, a scientist in the Department of Otolaryngology and F.M. Kirby Neurobiology Center at Boston Children's and an associate professor of Otolaryngology at Harvard Medical School.
Mice engineered to express Lin28 in their kidneys developed Wilms tumor, which regressed when Lin28 was withdrawn, indicating that strategies aimed at blocking or deactivating the
gene hold
therapeutic promise
for children with Wilms.
The study paves the way
for CRISPR - Cas9 as a powerful
gene editing tool with potential
therapeutic applications
for inherited diseases — leading to more widely available
gene therapy techniques.
The authors conclude that these
genes may represent new
therapeutic targets
for HD.
Remarkably, when the researchers manipulated the activity of these three
genes, almost all of the other
genes in the network were corrected, pointing to novel
therapeutic targets
for CAVD.
A comprehensive DNA sequencing of pancreatic cancer cases revealed not only a plethora of damaged
genes, but potential diagnostic biomarkers that could help identify those with longer or shorter survival, and provide opportunity
for new
therapeutic interventions.
«Importantly, the team was able to identify several
genes that may be able to help us to predict outcomes in certain circumstances or serve as good candidates
for therapeutic efforts.»
It would be very easy
for a team physician to let
therapeutic genes continue working
for a few hours, days, or weeks after an officially sanctioned treatment ends.
By searching
for gene deletion patterns in cancer through a concept the investigators call «synthetic essentiality,» the team identified a synthetic essential
gene known as chromatin helicase DNA - binding factor (CHD1) as a
therapeutic target
for prostate and breast cancers lacking a tumor suppressor
gene called phosphatase and tensin homolog (PTEN).
A new method has been found
for identifying
therapeutic targets in cancers lacking specific key tumor suppressor
genes.
Hilbert recommends to test
therapeutic phages
for their ability to transfer resistance
genes.
The team used
gene expression profiling and found that canine B - cell lymphoma expression profiles were similar in many ways to human B - cell lymphoma, thus paving the way
for future studies, including
therapeutic clinical trials in dogs and humans.
It will also have to be adapted to carry
genes large enough to code
for many
therapeutic proteins.
Their work could overcome a stumbling block
for gene therapy by ensuring that a
gene is actually inserted into a target cell's chromosome, where it will order the production of
therapeutic proteins.
Several researchers worldwide are trying to delete disease
genes for therapeutic reasons.
«Body's own
gene editing system generates leukemia stem cells: Inhibiting the editing enzyme may provide a new
therapeutic approach
for blood cancers.»
Whilst a handful of these
genes including DOT1L, BCL2 and MEN1 are already established
therapeutic targets, most of them are novel and open up many new possibilities
for developing effective treatments against the disease.
«A better understanding of the brain region and cell type - specific binding targets of Hnrnph1 will tell us more about the function of this
gene and possibly identify new
therapeutic strategies
for minimizing risk and treating psychostimulant addiction — a disorder
for which there is currently no FDA - approved drug,» explained corresponding author Camron Bryant, PhD, assistant professor of Pharmacology and Experimental Therapeutics & Psychiatry at BUSM.
Targeted
gene therapies, however, had to wait
for (1) the identification of the
genes to target, (2) the cloning and / or sequencing of the relevant
genes and in some cases, the specific disease - causing variant, (3) a full understanding of the normal
gene function and regulation, and (4) the development of efficient ways to deliver
genes to the relevant tissues at
therapeutic levels.
The identification of
genes that are synthetically lethal in β - catenin - activated cancer cells would provide new targets
for therapeutic drug design.
This study is good example of a precision medicine themed approach to showing how a mechanistic understanding of the differential
gene expression can yield biomarkers that can be used
for early detection of disease, as well as potential
therapeutic targets.
Since then he has continued to investigate new strategies to overcome the major hurdles to safe and effective
gene transfer, translate then into new
therapeutic strategies
for genetic disease and cancer, and allowed new insights into hematopoietic stem cell function, induction of immunological tolerance and tumor angiogenesis.
Next we use such assays to identify LEAD chemical compound (s) with
therapeutic potential
for HD or to validate drug or
gene - based
therapeutic approaches developed by our collaborators (Pr.
The advancement of the Cas9 - based platform
for screening and validation will help further the development of new
therapeutic products, and Caribou's CRISPR - Cas9 technology can utilize guide RNAs specific
for unique sequences and target a
gene at numerous sites and therefore provide enhanced specificity.
Therapeutic applications of CRISPR - Cas
gene editing are being advanced with the goals of finding cures and treatments
for a range of serious diseases, developing needed medicines
for both household pets and production animals, and improving cell culture systems
for bioproduction.
How Parkinson's
Gene may lead to New
Therapeutic Strategies
for Breast Cancer MyCentralJersey.com — December 1, 2017
Using tiny snippets of DNA as «barcodes,» researchers have developed a new technique
for rapidly screening the ability of nanoparticles to selectively deliver
therapeutic genes to specific organs of the body.
This technology helps researchers connect mutations in the so - called genomic «dark matter» with the
genes they affect, potentially revealing new
therapeutic targets
for genetic disorders.
This call
for projects «Mouse models and rare diseases» aims to give a significant boost to the development of mouse models, in order to: ◊ gain a better understanding of the pathophysiological mechanisms involved in rare diseases whose defective
genes have been identified ◊ test and validate
therapeutic proofs of concept, at the pre-clinical in vivo level Indeed, producing these models meets a key objective in the development of a
therapeutic strategy.
The goal is to understand the role of these
genes and proteins and to see if they are involved in various diseases, and thus may one day serve as viable targets
for therapeutic treatments.
«In our study, we used a
gene therapeutic approach, but you could purify the modified protein and inject it intravenously just like it is already done
for enzyme replacement therapy,» explains Spencer.
With the reference cell census data in hand, the research team is excited to conduct additional studies, including ones involving models or human patients with gastrointestinal conditions — Crohn's disease, ulcerative colitis, gastrointestinal cancers, forms of food allergy, etc. — aimed at identifying changes in
gene expression and epithelial structure and function that could reveal new insights and opportunities
for therapeutic development.
PrediXcan has the potential to identify
gene targets
for therapeutic applications faster and with greater accuracy than traditional methods.
I look
for genes, pathways, and candidate mutations associated with a disease, in order to understand the mechanism and the etiology of a disease, which may eventually lead to new
therapeutic targets.
In the 1980s, Dr. Kaufman's experience with
gene transfer and engineering led him to become a founding scientist at Genetics Institute Inc., where he engineered mammalian cells
for high - level expression of
therapeutic proteins, such as clotting factors that are now used to treat individuals with hemophilia.
Following Dr. Mendell's successful phase I trial described in the NEJM publication, additional studies to enable FDA approval of the first
gene therapeutic for a fatal disease of infants are now underway.
This molecule brings a revolutionary technology platform
for genetic engineering in vertebrates, including
gene discovery in model species and
for therapeutic transgene delivery
for possible human applications.